钠-葡萄糖转运体2抑制剂坎格列净的药理与临床评价  

Pharmacological Actions and Clinical Evaluation of Canagliflozin-an Inhibitor of Sodium-glucose Transporter 2

作　　者：陈露露[1] 封宇飞[1] 

机构地区：[1]北京医院药学部,北京市100730

出　　处：《中国全科医学》2014年第35期4242-4244,共3页Chinese General Practice

摘　　要：坎格列净是一种钠-葡萄糖转运体2抑制剂,也是一种新型降糖药,临床上用于食物和运动控制不佳的2型糖尿病。坎格列净于2013年在美国批准上市,目前现有的研究显示其安全有效、耐受良好。本文通过检索Pub Med数据库有关坎格列净的文献,对其作用机制、药效学、药动学、临床评价、用法用量、药物相互作用和安全性进行综述。Canagliflozin is a sodium-glucose transporter 2（ SGLT2） inhibitor and a new type of hypoglycemic drug. It is used in clinic to improve glycemic control in auxiliary type 2 diabetes poorly controlled by food and exercises. Canagliflozin was approved in America in 2013 and all the current clinical studies have demonstrated that canagliflozin is effective,safe and well tolerated. A literature search is conducted using Pub Med with the key words canagliflozin. The mechanism of action,pharmacodynamics,pharmacokinetics,clinical evaluation,usage,dosage,drug interactions and safety are reviewed in this paper.

关 键 词：钠-葡萄糖转运体2 糖尿病 2型 坎格列净 药理作用 

分 类 号：R587.1[医药卫生—内分泌]